Al-Achi A (2008). An Introduction to Botanical Medicines: History, Science, Uses, and Dangers: History, Science, Uses, and Dangers, ABC-CLIO.

Ambler RA Coulson JM, Frere JM, Ghuysen B, Joris M, Forsman R Levesque G, Tiraby S, Waley (1991). A standard numbering scheme for the class A beta-lactamases. Biochem. J. 276(1):269.
Crossref

Amin NE, Giske CG, Jalal S, Keijser B, Kronvall G, Wretlind B (2005). Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates. Apmis 113(3):187-196.
Crossref

Bauer A, Kirby W, Sherris J, turck C, Turck M (1966). Antibiotic susceptibility testing by a standardized single disk method. Am. J. Clin. Pathol. 45(4):493.

Brooks GF, Butel JS, Ornston LN (2005). Microbial Genetics. In: Jawetz and Adelberg's Medical Microbiology. Lange Medical Book, 20th ed: Pp.86-104.

Butler DA, Lobregat C, Gavan TL (1975). Reproducibility of the analytab (API 20E) system. J. Clin. Microbiol. 2(4):322-326.

Cheesbrough M (2006). District laboratory practice in tropical countries, Cambridge university press.
Crossref

CLSI (2013). Performance standards for antimicrobial susceptibility testing; Twenty- third informational supplement.CLSI document M100-S23. Wayne, PA, USA.

Eisner A, Fagan EJ, Feierl G, Kessler HH, Marth E, Livermore DM, Woodford N (2006). Emergence of Enterobacteriaceae isolates producing CTX-M extended-spectrum β-lactamase in Austria. Antimicrob. Agents Chemother. 50(2):785-787.
Crossref

Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ (2011). International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin. Infect. Dis. 52(5):e103-e120.
Crossref

Gupta K, Sahm DF, Mayfield D, Stamm WE (2001). Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis. Clin. Infect. Dis. 33(1): 89-94.
Crossref

Gupta V (2007). An update on newer [beta]-lactamases. Indian J. Med. Res. 126(5):417.

Hosoglu S, Gundes S, Kolayli F, Karadenizli A, Demirdag K, Gunaydin M, Altindis M, Caylan R, Ucmak H (2007). Extended-spectrum beta-lactamases in ceftazidime-resistant Escherichia coli and Klebsiella pneumoniae isolates in Turkish hospitals. Indian J. Med. Microbiol. 25(4):346.
Crossref

Ibrahim MA, Agban MN, Thabit AG, El-Khamissy TR, Attia AE (2014). Prevalence of Extended-Spectrum β-Lactamase producing Klebsiella pneumoniae by phenotypic and genotypic methods in Assiut University Hospital. Egypt J. Med. Microbiol. 23(4).
Crossref

Livermore DM (1995). beta-Lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8(4):557-584.

McGinnis S, Madden TL (2004). BLAST: at the core of a powerful and diverse set of sequence analysis tools. Nucleic Acids Res. 32(2):W20-W25.
Crossref

Mendonça N, Ferreira E, Louro D, Participants A, Caniça M (2009). Molecular epidemiology and antimicrobial susceptibility of extended-and broad-spectrum β-lactamase-producing Klebsiella pneumoniae isolated in Portugal. Int. J. Antimicrob. Agents 34(1):29-37.
Crossref

Mortensen JE, Bernier M, Gray LD, Dolan S, Hanson ND, Moland ES, Abdalhamid B (2005). New quality control strain for use in routine testing for production of extended-spectrum beta-lactamases by Enterobacteriaceae. J. Clin. Microbiol. 43(5):2545-2545.
Crossref

Nicolle L (2005). Complicated urinary tract infection in adults. Can. J. Infect. Dis. Med. Microbiol. 16(6):349.
Crossref

Oliver A, Weigel LM, Rasheed JK, McGowan JE, Raney P, Tenover FC (2002). Mechanisms of decreased susceptibility to cefpodoxime in Escherichia coli. Antimicrob. Agents Chemother. 46(12):3829-3836.
Crossref

Pagani L, Dell'Amico E, Migliavacca R, D'Andrea MM, Giacobone E, Amicosante G, Romero E, Rossolini GM (2003). Multiple CTX-M-type extended-spectrum β-lactamases in nosocomial isolates of Enterobacteriaceae from a hospital in northern Italy. J. Clin. Microbiol. 41(9):4264-4269.
Crossref

Paterson DL, Bonomo RA (2005). Extended-spectrum β-lactamases: a clinical update. Clin. Microbiol. Rev. 18(4):657-686.
Crossref

Peladan F, Monteil H (1988). Identification of Pseudomonas, Flavobacterium, and Alcaligenes with the API 20 NE system. Pathol. Biol. 36(2):187-192.

Philippon A, Arlet G, Jacoby GA (2002). Plasmid-determined AmpC-type β-lactamases. Antimicrob. Agents Chemother. 46(1):1-11.
Crossref

Poirel L, Gniadkowski M, Nordmann P (2002). Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum β-lactamase CTX-M-15 and of its structurally related β-lactamase CTX-M-3. J. Antimicrob. Chemother. 50(6):1031-1034.
Crossref

Sanger F, Nicklen S, Coulson AR (1977). DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. U.S.A. 74(12):5463-5467.
Crossref

Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Sِding J (2011). Fast, scalable generation of high‐quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol. 7(1).

Stürenburg E, Mack D (2003). Extended-spectrum β-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control. J. Infect. 47(4):273-295.
Crossref

Thabit AG, El-Khamissy TR, Ibrahim MA, Attia AE (2011). Detection of extendedspectrum beta-lactamase enzymes (ESBLS) produced by Escherichia coli urinary pathogens at assiut university hospital. Bull. Pharm. Sci, Assiut University 34(2):93-103.

Thomson K, Sanders W, Sanders C (1994). USA resistance patterns among UTI pathogens. J. Antimicrob. Chemother. 33(suppl A):9-15.
Crossref